Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Calcineurin Inhibitor Pain Syndrome: A Case Report & Literature Review

Priyanka Iyer, MD, MPH  |  Issue: March 2019  |  March 18, 2019

CHICAGO—Medications have frequently been implicated as a cause of musculoskeletal complaints, including persistent arthralgias, arthritis and myalgias.1 The list of offending agents is diverse, and the degree of symptoms is variable. In the world of transplant recipients, this list is exhaustive and includes immunosuppressive agents (cyclosporine, tacrolimus); myeloid growth factors, such as G-CSF; antibiotics (quinolones); and antifungal drugs (voriconazole).

Additional etiologies for musculoskeletal complaints may include hyperuricemia and gouty arthritis, osteoporosis, aseptic necrosis of the femoral head and septic arthritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Calcineurin inhibitor pain syndrome (CIPS) is a rare syndrome, characterized by symmetric lower extremity arthralgias and long bone pain, seen among patients currently on treatment with calcineurin inhibitors.

Below, we discuss the case of a patient who presented with bilateral symmetric knee pain while on cyclosporine. Our case highlights the importance of keeping CIPS on the differential diagnosis when a transplant recipient presents with arthralgias and bone pain. It also elucidates the challenges of treating this entity.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Case Report

A 53-year-old man who had received a liver transplant for a diagnosis of alcoholic cirrhosis was referred to the rheumatology clinic for unremitting knee and lower extremity pain, fatigue and myalgias.

Approximately one month after his transplant, he complained of polyarthralgia, predominantly affecting the large joints (shoulders, knees, back and ankles), for which he had been treated with prednisone. Consequently, most of his arthralgias resolved, except for persistent knee pain.

He was then evaluated at his primary care physician’s office, where a physical examination revealed bilateral crepitus in his knees. Knee X-rays showed evidence of bilateral, medial joint space narrowing (see Figures 1 and 2). An initial diagnosis of osteoarthritis was made, and he was referred to physical therapy for quadriceps strengthening.

Within six months, however, the patient’s pain had significantly worsened. He couldn’t walk without assistance and, consequently, needed crutches. At this time, about a year after his transplant, he was referred to the rheumatology clinic.

In the clinic, the patient described intense, constant pain, primarily in both knees, but also affecting his legs. This was constant, disabling and present throughout the day, without a morning predilection. His past medical history was significant for hypothyroidism, hypertension and gastroesophageal reflux disease. He was on several medications, including cyclosporine for immunosuppression and acetaminophen, which he used as an analgesic.

The musculoskeletal exam was notable for bilateral quadriceps atrophy, crepitus in the knees and small, bilateral knee effusions. The rest of his physical examination proved unremarkable.

The initial laboratory workup revealed mild anemia (hemoglobin 11.4 g/dL), an elevated sedimentation rate (64 mm/hr) and an elevated alkaline phosphatase (ALP) level (261 U/L). Because his other markers of liver function were normal, a bone-specific alkaline phosphatase was checked, which returned elevated (30 µg/L). The remainder of his labs were unremarkable.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsMeeting Reports Tagged with:2018 ACR/ARHP Annual Meetingcalcineurin inhibitorcalcineurin inhibitor pain syndromeimmunosuppressive drugs

Related Articles

    Changing Our Thinking on Osteoarthritis

    March 1, 2010

    It’s time we changed our thinking on osteoarthritis

    Ethics Forum: What to Do When an Autoimmune Patient Needs a Transplant?

    March 19, 2018

    Despite our best efforts and modern interventions, we still have patients in the intensive care unit with organ failure. Although renal failure can be mitigated by dialysis, patients with cardiac or respiratory failure secondary to active autoimmune disease raise difficult clinical and ethical issues. Two recent cases, both with organ failure, led us to examine…

    HSCT for Severe Autoimmune Diseases

    HSCT for Severe Autoimmune Diseases

    August 14, 2017

    Despite the innovations of new biologics and disease-modifying anti-rheumatic drugs, a large unmet need remains for patients with rheumatic autoimmune disease. Treatment remains limited for many conditions, including for conditions with a dim prognosis, such as systemic sclerosis.1 One promising treatment avenue is hematopoietic stem-cell transplantation (HSCT). Here, we provide background on HSCT for severe…

    A Duet of Bone and the Immune System

    July 12, 2011

    Examining emerging perspectives in osteoimmunology

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences